James Chih-Hsin Yang Selected Research

Afatinib

6/2023	Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations.
2/2023	Afatinib for the treatment of non-small-cell lung cancer with unusual EGFR mutations: a plain language summary.
1/2022	Sequential Afatinib and Osimertinib in Asian Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer and Acquired T790M: Combined Analysis of Two Global Non-Interventional Studies.
1/2022	Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report.
1/2020	The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation.
1/2020	Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases.
8/2019	Improving the anticancer effect of afatinib and microRNA by using lipid polymeric nanoparticles conjugated with dual pH-responsive and targeting peptides.
6/2019	First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression.
1/2019	First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting.
1/2019	Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

James Chih-Hsin Yang Research Topics

Disease

122	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 02/2024 - 01/2011
61	Neoplasms (Cancer) 01/2024 - 07/2011
38	Lung Neoplasms (Lung Cancer) 12/2023 - 11/2011
29	Disease Progression 01/2024 - 10/2011
20	Adenocarcinoma of Lung 06/2023 - 05/2012
17	Neoplasm Metastasis (Metastasis) 12/2023 - 10/2013
16	Diarrhea 04/2024 - 08/2011
12	Exanthema (Rash) 06/2023 - 05/2012
9	Fatigue 06/2023 - 08/2011
8	Brain Neoplasms (Brain Tumor) 01/2023 - 10/2013
7	Adenocarcinoma 01/2020 - 07/2011
6	Nausea 06/2023 - 08/2011
5	Dyspnea (Shortness of Breath) 06/2023 - 02/2013
5	Pain (Aches) 06/2023 - 02/2013
5	Acne Vulgaris 06/2023 - 05/2012
5	Cough 06/2023 - 02/2013
5	Epilepsy (Aura) 04/2018 - 10/2016
4	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 04/2024 - 01/2020
4	Neutropenia 04/2024 - 02/2015
4	Stomatitis 06/2023 - 09/2013
3	Anemia 04/2024 - 01/2020
3	Central Nervous System Diseases (CNS Diseases) 01/2023 - 12/2016
2	Edema (Dropsy) 04/2024 - 11/2018
2	Vomiting 02/2021 - 02/2015
2	Acute Kidney Injury (Acute Renal Failure) 01/2020 - 11/2016
2	Colonic Neoplasms (Colon Cancer) 08/2019 - 07/2012
2	Hypertension (High Blood Pressure) 11/2017 - 08/2011
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2017 - 03/2015
2	Malignant Pleural Effusion 01/2017 - 11/2013
2	Sepsis (Septicemia) 11/2016 - 05/2014
2	Renal Insufficiency (Renal Failure) 01/2016 - 06/2013
2	Deglutition Disorders (Dysphagia) 09/2013 - 02/2013
1	Leukopenia 04/2024
1	Thrombosis (Thrombus) 10/2023
1	Neuroendocrine Carcinoma 01/2023

Drug/Important Bio-Agent (IBA)

76	ErbB Receptors (EGF Receptor)IBA 01/2024 - 01/2011
59	Tyrosine Kinase InhibitorsIBA 01/2024 - 01/2011
35	Gefitinib (Iressa)FDA Link 12/2023 - 01/2011
28	AfatinibIBA 06/2023 - 05/2012
26	osimertinibIBA 01/2024 - 04/2015
21	PlatinumIBA 01/2024 - 10/2011
15	Pemetrexed (MTA)FDA Link 12/2023 - 08/2012
15	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2019 - 01/2011
11	CrizotinibIBA 12/2023 - 05/2014
10	Cisplatin (Platino)FDA LinkGeneric 10/2023 - 08/2012
10	Biomarkers (Surrogate Marker)IBA 01/2023 - 07/2011
9	DNA (Deoxyribonucleic Acid)IBA 12/2023 - 01/2017
9	Anaplastic Lymphoma KinaseIBA 11/2021 - 09/2015
8	pembrolizumabIBA 12/2023 - 11/2016
8	alectinibIBA 12/2023 - 01/2016
7	Immune Checkpoint InhibitorsIBA 02/2024 - 08/2019
5	Paclitaxel (Taxol)FDA LinkGeneric 02/2021 - 07/2011
5	Carboplatin (JM8)FDA LinkGeneric 11/2017 - 07/2011
4	Docetaxel (Taxotere)FDA Link 03/2021 - 07/2013
3	NivolumabIBA 01/2024 - 01/2018
3	LigandsIBA 12/2023 - 01/2023
3	Cell-Free Nucleic AcidsIBA 12/2023 - 01/2017
3	brigatinibIBA 12/2023 - 11/2018
3	Phosphotransferases (Kinase)IBA 01/2023 - 05/2015
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2020 - 01/2016
2	CreatinineIBA 04/2024 - 01/2023
2	lenvatinibIBA 12/2023 - 01/2023
2	lazertinibIBA 12/2023 - 10/2023
2	Adrenal Cortex Hormones (Corticosteroids)IBA 09/2023 - 04/2017
2	1- (1- (imidazo(1,2- a)pyridin- 6- yl)ethyl)- 6- (1- methyl- 1H- pyrazol- 4- yl)- 1H- (1,2,3)triazolo(4,5- b)pyrazineIBA 01/2023 - 01/2020
2	mobocertinibIBA 01/2023 - 12/2021
2	Lipase (Acid Lipase)FDA Link 01/2023 - 11/2018
2	durvalumabIBA 09/2022 - 01/2019
2	amivantamab-vmjwIBA 01/2022 - 10/2021
2	tepotinibIBA 01/2022 - 11/2020
2	Gemcitabine FDA Link 02/2021 - 06/2012
2	rociletinibIBA 02/2021 - 10/2016
2	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2020 - 11/2017
2	Circulating Tumor DNAIBA 08/2019 - 12/2015
2	AZD3759IBA 11/2017 - 12/2016
2	RNA (Ribonucleic Acid)IBA 01/2017 - 12/2013
2	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 01/2016 - 09/2015
2	Bevacizumab (Avastin)FDA Link 09/2014 - 11/2013
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 02/2013 - 07/2012
1	Topotecan (Hycamtin)FDA LinkGeneric 04/2024
1	Irinotecan (Camptosar)FDA LinkGeneric 04/2024
1	SteroidsIBA 12/2023
1	trastuzumab deruxtecanIBA 11/2023
1	NucleotidesIBA 11/2023
1	Complement System Proteins (Complement)IBA 11/2023
1	canakinumab FDA Link 10/2023
1	InterleukinsIBA 10/2023
1	avelumabIBA 09/2023
1	Chimeric Antigen ReceptorsIBA 01/2023
1	Immunoconjugates (Immunoconjugate)IBA 01/2023
1	Tumor Biomarkers (Tumor Markers)IBA 01/2023
1	selpercatinibIBA 09/2022
1	AZD 6244IBA 06/2022

Therapy/Procedure

54	Drug Therapy (Chemotherapy) 01/2024 - 10/2011
50	Therapeutics 01/2024 - 08/2011
7	Radiotherapy 01/2022 - 01/2015
3	Time-to-Treatment 01/2022 - 01/2019
3	Immunotherapy 03/2021 - 01/2018
2	Cranial Irradiation 01/2021 - 12/2019
2	Aftercare (After-Treatment) 01/2018 - 06/2015